市場調查報告書

PEG化製劑的全球市場分析 - 2025年為止的預測

Global PEGylated Drugs Market Research Report - Forecast till 2025

出版商 Market Research Future 商品編碼 922980
出版日期 內容資訊 英文 103 Pages
訂單完成後即時交付
價格
PEG化製劑的全球市場分析 - 2025年為止的預測 Global PEGylated Drugs Market Research Report - Forecast till 2025
出版日期: 2019年12月01日內容資訊: 英文 103 Pages
簡介

預計到2025年,全球PEG化藥物市場的複合年增長率將達到5.53%,市場規模為1353.6萬美元。聚乙二醇化是將聚乙二醇聚合物鏈共價和非共價連接到生物活性分子(蛋白質,肽,酶,抗體片段,寡核苷酸等)的過程。這是在臨床環境中增強藥物治療效果的有潛力技術。一些PEG化產品已獲得美國食品藥品監督管理局(FDA)的批准,許多藥物正在接受臨床試驗。領先的公司正在投資研發聚乙二醇化產品。癌症等慢性疾病的流行率增長,製藥業的增長以及生物製劑的發推動了全球PEG藥品市場的成長。

本報告提供全球PEG化製劑市場調查,提供市場概要,各分子類型·適應症·各地區的市場規模的變化與預測,市場成長要素及阻礙因素分析,市場機會,價值鏈及波特的五力分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

目錄

第1章 摘要整理

  • 全球聚乙二醇化製劑市場:各分子類型
  • 全球聚乙二醇化製劑市場:各適應症

第2章 市場簡介

  • 定義
  • 調查範圍
  • 調查目的
  • 市場結構

第3章 調查方法

  • 調查方法
  • 一次調查
  • 二次調查
  • 市場規模推算
  • 預測模式
  • 假設的清單

第4章 市場動態

  • 簡介
  • 成長要素
    • 癌症等慢性疾病的盛行率上升
    • 增長的製藥產業
    • 生技藥品的進步
  • 阻礙因素
    • 聚乙二醇化製劑相關的副作用
    • 醫藥品回收
  • 市場機會
    • 聚乙二醇化製劑的強力開發平台

第5章 市場影響要素分析

  • 價值鏈分析
    • 研究開發
    • 製造
    • 流通·銷售
    • 製造銷售後安全管理
  • 波特的五力分析

第6章 全球PEG化製劑市場:各分子類型

  • 概要
  • 蛋白質
  • FAB片段
  • 酵素
  • 核酸適體

第7章 全球PEG化製劑市場:各適應症

  • 概要
  • 癌症
  • 痛風
  • 血友病
  • 肝炎

第8章 全球PEG化製劑市場:各價值階段

  • 概要
  • 南北美洲
    • 北美
    • 南美
  • 歐洲
    • 西歐
    • 東歐
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區
  • 中東·非洲
    • 中東
    • 非洲

第9章 競爭情形

  • 簡介
  • 主要的聚乙二醇化製劑

第10章 企業簡介

  • HORIZON THERAPEUTICS PLC
  • F. HOFFMANN-LA ROCHE LTD
  • PFIZER INC.
  • NOVO NORDISK A/S
  • UCB S.A.
  • AMGEN, INC.
  • ASTRAZENECA
  • MERCK & CO., INC.
  • 武田藥品工業
  • BAYER AG

第11章 附錄

  • 參考文獻
  • 相關報告
目錄

Global PEGylated Drugs Market: Information by Molecule (Protein, FAB' Fragment, Enzyme and Aptamer), by Indication (Cancer, Gout, Hemophilia and Hepatitis) and by Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2025

Market Analysis:

PEGylation refers to the process of covalent and non-covalent attachment of polyethylene glycol polymer chains to bioactive molecules (proteins, peptides, enzymes, antibody fragments, oligonucleotides, etc.). It is a promising technique to enhance therapeutic effectiveness of medicines in clinical settings. Several PEGylated drugs have been approved by the Food and Drug Administration (FDA), and many drugs are being tested in clinical settings. The major companies are strictly investing in R&D of PEGylated drugs and have good number of molecules in the pipeline. So for example, UCB and Biogen are assessing safety and effectiveness of dapirolizumab pegol. Dapirolizumab pegol is an anti-CD40L pegylated Fab and is in Phase 2b of the clinical trial. The drug is developed for the treatment of systemic lupus erythematosus. However, adverse reactions associated with PEGylated drugs and drug recalls are anticipated to restrain the growth of the global PEGylated drugs market during the forecast period. The Global PEGylated Drugs Market is rising due to the growth in the spread of chronic diseases such as cancer, growing pharmaceutical industry, and advancements in the biologics sector. So for example, according to data from the National Cancer Institute, in the year 2016, 15.5 million new cases of cancer have been registered, and approximately USD 147.3 billion were spent for cancer care in the US. This rising prevalence of cancer creates a demand for effective drugs. Usage of advanced drug delivery system with PEGylation technology is important in the field of anti-cancer therapy as PEGylating enhances retention time of therapeutics which in turn is expected to increase growth of the global PEGylated drugs market. PEGylated Drugs Market is forecast to register a CAGR of 5.53% to reach USD 13,503.67 Million by 2025.

Market Segmentation:

The Global PEGylated Drugs Market has been segmented by Molecule, Indication and region. By Molecule The Global PEGylated Drugs Market has been segmented into Protein, FAB' Fragment, Enzyme and Aptamer. PEGylated protein is anticipated to account for the leading market share of 64.80% during the forecast period. Rising demand for PEGylation, increase in a number of chronic diseases including cancer, and product launches by major market players are propelling the growth of this segment. Global PEGylated Drugs Market has been divided by Indication into Cancer, Gout, Hemophilia and Hepatitis. Geographically, the Global PEGylated Drugs Market has been split into regions like North America (US & Canada), Latin America, Europe (Germany, UK, France, Spain, Italy and Rest of Europe), Asia-Pacific (China, India, Japan, Australia & New Zealand, Southeast Asia and Rest of Asia-Pacific), Middle East & Africa.

Regional Analysis:

Geographically, The Global PEGylated Drugs Market is broadly segmented into different regions like Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is responsible for a market share of 65.73% in the year 2018. Americas is sub-segmented into North America and South America. North America has been further sub-segmented into the US and Canada. Europe was the second-largest Global PEGylated Drugs Market in the year 2018. The increasing efforts by the government to decrease persistent disease burden owing to the mounting occurrence of cancer in the region is estimated to push the market growth. The Europe region is further segmented into Western Europe and Eastern Europe. Western Europe, on the basis of countries has been, segmented into Germany, the UK, France, Italy, Spain, and the rest of Western Europe. The Asia-Pacific region has been categorized as China, India, Japan, Australia, South Korea and the rest of Asia-Pacific. It holds the third-largest position in the PEGylated drugs market. The Middle East & Africa is expected to witness a remarkable growth owing to the increasing applications PEGylated drugs for the treatment of chronic diseases.

Major Players:

Horizon Therapeutics Plc, F. Hoffmann-La Roche Ltd., Pfizer Inc., Novo Nordisk A/S, UCB S.A., Amgen, Inc., AstraZeneca, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, and Bayer AG are some of the prominent players in The Global PEGylated Drugs Market. The players operating in the global PEGylated Drugs Market are focusing on product launches, along with expanding their global footprints by entering untapped markets. Some of the projected onlooker for the global PEGylated Drugs Market are Academic research institutes, Pharmaceutical companies, Biotechnology Companies, PEGylation products manufacturing companies, Contract research organizations (CROs) and Market research & consulting firms.

Table of Contents

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

  • 1.1 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE
  • 1.2 GLOBAL PEGYLATED DRUGS MARKET, BY INDICATION

2 Market Introduction

  • 2.1 DEFINITION
  • 2.2 SCOPE OF THE STUDY
  • 2.3 RESEARCH OBJECTIVE
  • 2.4 MARKET STRUCTURE

3 Research Methodology

  • 3.1 RESEARCH PROCESS
  • 3.2 PRIMARY RESEARCH
  • 3.3 SECONDARY RESEARCH
  • 3.4 MARKET SIZE ESTIMATION
  • 3.5 FORECAST MODEL
  • 3.6 LIST OF ASSUMPTIONS

4 MARKET DYNAMICS

  • 4.1 INTRODUCTION
  • 4.2 DRIVERS
    • 4.2.1 INCREASE IN THE PREVALENCE OF CHRONIC DISEASES SUCH AS CANCER
    • 4.2.2 GROWING PHARMACEUTICAL INDUSTRY
    • 4.2.3 ADVANCEMENT IN THE BIOLOGICS SECTOR
  • 4.3 RESTRAINTS
    • 4.3.1 ADVERSE DRUG REACTIONS ASSOCIATED WITH PEGYLATED DRUGS
    • 4.3.2 DRUG RECALL
  • 4.4 OPPORTUNITIES
    • 4.4.1 STRONG PIPELINE FOR PEGYLATED DRUGS

5 MARKET FACTOR ANALYSIS

  • 5.1 VALUE CHAIN ANALYSIS
    • 5.1.1 R&D
    • 5.1.2 MANUFACTURING
    • 5.1.3 DISTRIBUTION & SALES
    • 5.1.4 POST-SALES MONITORING
  • 5.2 PORTER'S FIVE FORCES MODEL
    • 5.2.1 THREAT OF NEW ENTRANTS
    • 5.2.2 BARGAINING POWER OF SUPPLIERS
    • 5.2.3 BARGAINING POWER OF BUYERS
    • 5.2.4 THREAT OF SUBSTITUTES
    • 5.2.5 INTENSITY OF RIVALRY

6 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE

  • 6.1 OVERVIEW
  • 6.2 PROTEIN
  • 6.3 FAB' FRAGMENT
  • 6.4 ENZYME
  • 6.5 APTAMER

7 GLOBAL PEGYLATED DRUGS MARKET, BY INDICATION

  • 7.1 OVERVIEW
  • 7.2 CANCER
  • 7.3 GOUT
  • 7.4 HEMOPHILIA
  • 7.5 HEPATITIS

8 GLOBAL PEGYLATED DRUGS MARKET, BY REGION

  • 8.1 OVERVIEW
  • 8.2 AMERICAs
    • 8.2.1 NORTH AMERICA
    • 8.2.2 LATIN AMERICA
  • 8.3 EUROPE
    • 8.3.1 WESTERN EUROPE
    • 8.3.2 EASTERN EUROPE
  • 8.4 ASIA-PACIFIC
    • 8.4.1 JAPAN
    • 8.4.2 CHINA
    • 8.4.3 INDIA
    • 8.4.4 AUSTRALIA
    • 8.4.5 SOUTH KOREA
    • 8.4.6 REST OF ASIA-PACIFIC
  • 8.5 MIDDLE EAST & AFRICA
    • 8.5.1 MIDDLE EAST
    • 8.5.2 AFRICA

9 COMPETITIVE LANDSCAPE

  • 9.1 INTRODUCTION
  • 9.2 MAJOR PEGYLATED DRUGS

10 COMPANY PROFILES

  • 10.1 HORIZON THERAPEUTICS PLC
    • 10.1.1 COMPANY OVERVIEW
    • 10.1.2 FINANCIAL OVERVIEW
    • 10.1.3 PRODUCTS/SERVICES OFFERED
    • 10.1.4 KEY DEVELOPMENTS
    • 10.1.5 SWOT ANALYSIS
    • 10.1.6 KEY STRATEGIES
  • 10.2 F. HOFFMANN-LA ROCHE LTD
    • 10.2.1 COMPANY OVERVIEW
    • 10.2.2 FINANCIAL OVERVIEW
    • 10.2.3 PRODUCTS/SERVICES OFFERED
    • 10.2.4 KEY DEVELOPMENTS
    • 10.2.5 SWOT ANALYSIS
    • 10.2.6 KEY STRATEGIES
  • 10.3 PFIZER INC.
    • 10.3.1 COMPANY OVERVIEW
    • 10.3.2 FINANCIAL OVERVIEW
    • 10.3.3 PRODUCTS/SERVICES OFFERED
    • 10.3.4 KEY DEVELOPMENTS
    • 10.3.5 SWOT ANALYSIS
    • 10.3.6 KEY STRATEGIES
  • 10.4 NOVO NORDISK A/S
    • 10.4.1 COMPANY OVERVIEW
    • 10.4.2 FINANCIAL OVERVIEW
    • 10.4.3 PRODUCTS/SERVICES OFFERED
    • 10.4.4 KEY DEVELOPMENTS
    • 10.4.5 SWOT ANALYSIS
    • 10.4.6 KEY STRATEGIES
  • 10.5 UCB S.A.
    • 10.5.1 COMPANY OVERVIEW
    • 10.5.2 FINANCIAL OVERVIEW
    • 10.5.3 PRODUCTS/SERVICES OFFERED
    • 10.5.4 KEY DEVELOPMENTS
    • 10.5.5 SWOT ANALYSIS
    • 10.5.6 KEY STRATEGIES
  • 10.6 AMGEN, INC.
    • 10.6.1 COMPANY OVERVIEW
    • 10.6.2 FINANCIAL OVERVIEW
    • 10.6.3 Products/Services Offered
    • 10.6.4 KEY DEVELOPMENTS
    • 10.6.5 KEY STRATEGIES
  • 10.7 ASTRAZENECA
    • 10.7.1 COMPANY OVERVIEW
    • 10.7.2 FINANCIAL OVERVIEW
    • 10.7.3 PRODUCTS/SERVICES OFFERED
    • 10.7.4 KEY DEVELOPMENTS
    • 10.7.5 SWOT ANALYSIS
    • 10.7.6 KEY STRATEGIES
  • 10.8 MERCK & CO., INC.
    • 10.8.1 COMPANY OVERVIEW
    • 10.8.2 FINANCIAL OVERVIEW
    • 10.8.3 PRODUCTS/SERVICES OFFERED
    • 10.8.4 KEY DEVELOPMENTS
    • 10.8.5 SWOT ANALYSIS
    • 10.8.6 KEY STRATEGIES
  • 10.9 TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • 10.9.1 COMPANY OVERVIEW
    • 10.9.2 FINANCIAL OVERVIEW
    • 10.9.3 PRODUCTS/SERVICES OFFERED
    • 10.9.4 KEY DEVELOPMENTS
    • 10.9.5 SWOT ANALYSIS
    • 10.9.6 KEY STRATEGIES
  • 10.10 BAYER AG
    • 10.10.1 COMPANY OVERVIEW
    • 10.10.2 FINANCIAL OVERVIEW
    • 10.10.3 PRODUCTS/SERVICES OFFERED
    • 10.10.4 KEY DEVELOPMENTS
    • 10.10.5 SWOT ANALYSIS
    • 10.10.6 KEY STRATEGIES

11 APPENDIX

  • 11.1 REFERENCES
  • 11.2 RELATED REPORTS

List of Tables

LIST OF TABLES

  • TABLE 1 PRIMARY INTERVIEWS
  • TABLE 2 LIST OF ASSUMPTIONS
  • TABLE 3 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE 2016-2025 (USD MILLION)
  • TABLE 4 PROTEIN: MARKET ESTIMATES & FORECAST, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 5 FAB' FRAGMENT: MARKET ESTIMATES & FORECAST, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 6 ENZYME: MARKET ESTIMATES & FORECAST, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 7 APTAMER: MARKET ESTIMATES & FORECAST, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 8 GLOBAL PEGYLATED DRUGS MARKET, BY INDICATION 2016-2025 (USD MILLION)
  • TABLE 9 CANCER: MARKET ESTIMATES & FORECAST, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 10 GOUT: MARKET ESTIMATES & FORECAST, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 11 HEMOPHILIA: MARKET ESTIMATES & FORECAST, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 12 HEPATITIS: MARKET ESTIMATES & FORECAST, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 13 GLOBAL PEGYLATED DRUGS MARKET, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 14 AMERICAS: PEGYLATED DRUGS MARKET, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 15 AMERICAS: PEGYLATED DRUGS MARKET, BY MOLECULE, 2016-2025 (USD MILLION)
  • TABLE 16 AMERICAS: PEGYLATED DRUGS MARKET, BY INDICATION, 2016-2025 (USD MILLION)
  • TABLE 17 NORTH AMERICA: PEGYLATED DRUGS MARKET, BY COUNTRY, 2016-2025 (USD MILLION)
  • TABLE 18 NORTH AMERICA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2016-2025 (USD MILLION)
  • TABLE 19 NORTH AMERICA: PEGYLATED DRUGS MARKET, BY INDICATION, 2016-2025 (USD MILLION)
  • TABLE 20 US: PEGYLATED DRUGS MARKET, BY MOLECULE, 2016-2025 (USD MILLION)
  • TABLE 21 US: PEGYLATED DRUGS MARKET, BY INDICATION, 2016-2025 (USD MILLION)
  • TABLE 22 CANADA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2016-2025 (USD MILLION)
  • TABLE 23 CANADA: PEGYLATED DRUGS MARKET, BY INDICATION, 2016-2025 (USD MILLION)
  • TABLE 24 LATIN AMERICA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2016-2025 (USD MILLION)
  • TABLE 25 LATIN AMERICA: PEGYLATED DRUGS MARKET, BY INDICATION, 2016-2025 (USD MILLION)
  • TABLE 26 EUROPE: PEGYLATED DRUGS MARKET, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 27 EUROPE: PEGYLATED DRUGS MARKET, BY MOLECULE, 2016-2025 (USD MILLION)
  • TABLE 28 EUROPE: PEGYLATED DRUGS MARKET, BY INDICATION, 2016-2025 (USD MILLION)
  • TABLE 29 WESTERN EUROPE: PEGYLATED DRUGS MARKET, BY COUNTRY, 2016-2025 (USD MILLION)
  • TABLE 30 WESTERN EUROPE: PEGYLATED DRUGS MARKET, BY MOLECULE, 2016-2025 (USD MILLION)
  • TABLE 31 WESTERN EUROPE: PEGYLATED DRUGS MARKET, BY INDICATION, 2016-2025 (USD MILLION)
  • TABLE 32 GERMANY: PEGYLATED DRUGS MARKET, BY MOLECULE, 2016-2025 (USD MILLION)
  • TABLE 33 GERMANY: PEGYLATED DRUGS MARKET, BY INDICATION, 2016-2025 (USD MILLION)
  • TABLE 34 FRANCE: PEGYLATED DRUGS MARKET, BY MOLECULE, 2016-2025 (USD MILLION)
  • TABLE 35 FRANCE: PEGYLATED DRUGS MARKET, BY INDICATION, 2016-2025 (USD MILLION)
  • TABLE 36 UK: PEGYLATED DRUGS MARKET, BY MOLECULE, 2016-2025 (USD MILLION)
  • TABLE 37 UK: PEGYLATED DRUGS MARKET, BY INDICATION, 2016-2025 (USD MILLION)
  • TABLE 38 ITALY: PEGYLATED DRUGS MARKET, BY MOLECULE, 2016-2025 (USD MILLION)
  • TABLE 39 ITALY: PEGYLATED DRUGS MARKET, BY INDICATION, 2016-2025 (USD MILLION)
  • TABLE 40 SPAIN: PEGYLATED DRUGS MARKET, BY MOLECULE, 2016-2025 (USD MILLION)
  • TABLE 41 SPAIN: PEGYLATED DRUGS MARKET, BY INDICATION, 2016-2025 (USD MILLION)
  • TABLE 42 REST OF WESTERN EUROPE: PEGYLATED DRUGS MARKET, BY MOLECULE, 2016-2025 (USD MILLION)
  • TABLE 43 REST OF WESTERN EUROPE: PEGYLATED DRUGS MARKET, BY INDICATION, 2016-2025 (USD MILLION)
  • TABLE 44 EASTERN EUROPE: PEGYLATED DRUGS MARKET, BY MOLECULE, 2016-2025 (USD MILLION)
  • TABLE 45 EASTERN EUROPE: PEGYLATED DRUGS MARKET, BY INDICATION, 2016-2025 (USD MILLION)
  • TABLE 46 ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY COUNTRY, 2016-2025 (USD MILLION)
  • TABLE 47 ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY MOLECULE, 2016-2025 (USD MILLION)
  • TABLE 48 ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY INDICATION, 2016-2025 (USD MILLION)
  • TABLE 49 JAPAN: PEGYLATED DRUGS MARKET, BY MOLECULE, 2016-2025 (USD MILLION)
  • TABLE 50 JAPAN: PEGYLATED DRUGS MARKET, BY INDICATION, 2016-2025 (USD MILLION)
  • TABLE 51 CHINA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2016-2025 (USD MILLION)
  • TABLE 52 CHINA: PEGYLATED DRUGS MARKET, BY INDICATION, 2016-2025 (USD MILLION)
  • TABLE 53 INDIA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2016-2025 (USD MILLION)
  • TABLE 54 INDIA: PEGYLATED DRUGS MARKET, BY INDICATION, 2016-2025 (USD MILLION)
  • TABLE 55 AUSTRALIA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2016-2025 (USD MILLION)
  • TABLE 56 AUSTRALIA: PEGYLATED DRUGS MARKET, BY INDICATION, 2016-2025 (USD MILLION)
  • TABLE 57 SOUTH KOREA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2016-2025 (USD MILLION)
  • TABLE 58 SOUTH KOREA: PEGYLATED DRUGS MARKET, BY INDICATION, 2016-2025 (USD MILLION)
  • TABLE 59 REST OF ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY MOLECULE, 2016-2025 (USD MILLION)
  • TABLE 60 REST OF ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY INDICATION, 2016-2025 (USD MILLION)
  • TABLE 61 MIDDLE EAST & AFRICA: PEGYLATED DRUGS MARKET, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 62 MIDDLE EAST & AFRICA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2016-2025 (USD MILLION)
  • TABLE 63 MIDDLE EAST & AFRICA: PEGYLATED DRUGS MARKET, BY INDICATION, 2016-2025 (USD MILLION)
  • TABLE 64 MIDDLE EAST: PEGYLATED DRUGS MARKET, BY MOLECULE, 2016-2025 (USD MILLION)
  • TABLE 65 MIDDLE EAST: PEGYLATED DRUGS MARKET, BY INDICATION, 2016-2025 (USD MILLION)
  • TABLE 66 AFRICA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2016-2025 (USD MILLION)
  • TABLE 67 AFRICA: PEGYLATED DRUGS MARKET, BY INDICATION, 2016-2025 (USD MILLION)
  • TABLE 68 MAJOR PEGYLATED DRUGS
  • TABLE 69 PRODUCTS/SERVICES OFFERED
  • TABLE 70 KEY DEVELOPMENTS
  • TABLE 71 PRODUCTS PRODUCTS/SERVICES OFFERED
  • TABLE 72 PRODUCTS/SERVICES OFFERED
  • TABLE 73 KEY DEVELOPMENTS
  • TABLE 74 PRODUCTS/SERVICES OFFERED
  • TABLE 75 KEY DEVELOPMENTS
  • TABLE 76 PRODUCTS/SERVICES OFFERED
  • TABLE 77 KEY DEVELOPMENTS
  • TABLE 78 PRODUCTS/SERVICES OFFERED
  • TABLE 79 PRODUCTS/SERVICES OFFERED
  • TABLE 80 PRODUCTS/SERVICES OFFERED
  • TABLE 81 KEY DEVELOPMENTS
  • TABLE 82 PRODUCTS/SERVICES OFFERED
  • TABLE 83 KEY DEVELOPMENTS
  • TABLE 84 PRODUCTS/SERVICES OFFERED
  • TABLE 85 KEY DEVELOPMENTS 99

List of Figures

LIST OF FIGURES

  • FIGURE 1 MARKET SYNOPSIS
  • FIGURE 2 GLOBAL PEGYLATED DRUGS MARKET ANALYSIS, BY MOLECULE
  • FIGURE 3 GLOBAL PEGYLATED DRUGS MARKET ANALYSIS, BY INDICATION
  • FIGURE 4 GLOBAL PEGYLATED DRUGS MARKET: STRUCTURE
  • FIGURE 5 RESEARCH PROCESS
  • FIGURE 6 TOP-DOWN & BOTTOM-UP APPROACHES
  • FIGURE 7 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL PEGYLATED DRUGS MARKET
  • FIGURE 8 SUPPLY/VALUE CHAIN: GLOBAL PEGYLATED DRUGS MARKET
  • FIGURE 10 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE, 2018 (% SHARE)
  • FIGURE 11 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE, 2018 TO 2025 (USD MILLION)
  • FIGURE 12 GLOBAL PEGYLATED DRUGS MARKET, BY INDICATION, 2018 (% SHARE)
  • FIGURE 13 GLOBAL PEGYLATED DRUGS MARKET, BY INDICATION, 2018 TO 2025 (USD MILLION)
  • FIGURE 14 GLOBAL PEGYLATED DRUGS MARKET, BY REGION, 2018 AND 2025 (USD MILLION)
  • FIGURE 15 GLOBAL PEGYLATED DRUGS MARKET, BY REGION, 2018 (% SHARE)
  • FIGURE 16 AMERICAS: PEGYLATED DRUGS MARKET SHARE, BY REGION, 2018 (% SHARE)
  • FIGURE 17 EUROPE: PEGYLATED DRUGS MARKET SHARE, BY REGION, 2018 (% SHARE)
  • FIGURE 18 ASIA-PACIFIC: PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2018 (% SHARE)
  • FIGURE 19 MIDDLE EAST & AFRICA: PEGYLATED DRUGS MARKET SHARE, BY REGION, 2018 (% SHARE)
  • FIGURE 20 GLOBAL PEGYLATED DRUGS MARKET, SHARE ANALYSIS, 2018 (% SHARE)
  • FIGURE 21 FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 22 SWOT ANALYSIS
  • FIGURE 23 FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 24 SWOT ANALYSIS
  • FIGURE 25 FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 26 SWOT ANALYSIS
  • FIGURE 27 FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 28 SWOT ANALYSIS
  • FIGURE 29 FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 30 SWOT ANALYSIS
  • FIGURE 31 FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 32 SWOT ANALYSIS
  • FIGURE 33 FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 34 SWOT ANALYSIS
  • FIGURE 35 FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 36 SWOT ANALYSIS
  • FIGURE 37 FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 38 SWOT ANALYSIS
  • FIGURE 39 FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 40 SWOT ANALYSIS 99